Caitlin John’s Bicycle Therapeutics BCYC Stock Holding History

Caitlin John’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8	Hold	2	–	–	﹤0.01%	1000
2026 Q1	$9	Hold	2	–	–	﹤0.01%	934
2025 Q4	$14	Hold	2	–	–	﹤0.01%	922
2025 Q3	$15	Buy	+2	New	+$15	﹤0.01%	879
2025 Q1	–	Sell	-14	Closed	-$196	–	186
2024 Q4	$196	Hold	14	–	–	﹤0.01%	819
2024 Q3	$325	Hold	14	–	–	﹤0.01%	794
2024 Q2	$283	Buy	+14	New	+$316	﹤0.01%	798

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Caitlin John's BCYC Position: Q2 2026 in Review

Caitlin John held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 2 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

Caitlin John first reported a position in BCYC in Q2 2024 and has held it in 7 quarters since. The position peaked at $325 in Q3 2024. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Caitlin John held 2 shares of Bicycle Therapeutics worth $8 as of Q2 2026.
Caitlin John left its Bicycle Therapeutics share count unchanged in Q2 2026.
Bicycle Therapeutics made up ﹤0.01% of Caitlin John's portfolio in Q2 2026, its #1000 holding.
Caitlin John first reported a position in Bicycle Therapeutics in Q2 2024 and has held it in 7 quarters since.
Caitlin John's Bicycle Therapeutics position peaked at $325 in Q3 2024.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Caitlin John's 13F filing for Q2 2026, filed 17 Aug 2026.